FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machineton	D C	20540	
Washington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
Check this box to indicate that a	
transaction was made pursuant to a	
contract, instruction or written plan	
for the purchase or sale of equity	
securities of the issuer that is	

1. Name and Address of Reporting Person* <u>DiBiase Mary</u>			2. Issuer Name and Ticker or Trading Symbol X4 Pharmaceuticals, Inc [XFOR]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last) (First) (Middle) C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET 4TH FLOOR		3. Date of Earliest Transaction (Month/Day/Year) 10/04/2024									V	Officer (give title below) Chief Operating Officer Other (specify below)				specify			
(Street) BOSTO	N M	A 0	2134 Zip)		4. If <i>i</i>	Amend	ment,	Date	of Ori	ginal F	iled (Month/Da	ay/Year)		6. Indiv Line)	Form	filed by One	e Rep	ng (Check A porting Perso an One Repo	on
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				2A. Deemed Execution Date, if any			3. 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 are b)					5. Amount of		Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership			
Common Stock				10/04/2024		_		-	Code	v	Amount 230,645 ⁽¹⁾	(A) or (D)	Price \$(0	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
			10/07/202					S		67,695 ⁽²⁾	D	\$0.56	,				D		
		Tal	ole I								posed of, , convertib)wne	d			
Security or (Instr. 3) Pri	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Code (Instr.		umber vative urities uired or osed)) r. 3, 4	Exp (Mo	ate Exe iration nth/Day		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Deri Sec (Ins	vative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)
												Amount	t						

Explanation of Responses:

- 1. Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.
- 2. These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$0.55 to \$0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Adam S. Mostafa, attorney-10/08/2024 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.